Litigation

Celgene Corp. v. Natco Pharma Ltd. et al.

settled

2:10-cv-05197

Filed
2010-10-08
Terminated
2016-01-05

Patents at issue (1)

Plaintiffs (1)

Summary

Celgene brought this ANDA patent-infringement suit against Natco, Arrow, and Watson. The '717 patent was added by Fifth Amended Complaint on May 6, 2013, and the case settled on December 22, 2015, with a license to market generic lenalidomide beginning January 31, 2026; the docket terminated January 5, 2016.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

In the news

What the press has reported about this case, summarized with links to the source articles.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).